Qoria (ASX:QOR) has executed a deal with Japan’s SoftBank “to bring … digital wellbeing and parental control solutions to Japanese families in early 2025.”
Through its subsidiary Qustodio, Qoria has inked a deal with SoftBank subsidiary BBSS Corporation, another web security services player.
As far as Qoria sees it, there’s growing demand for web control tech in Japan.
Qustodio mostly designs solutions targeting children, where schools and families are the biggest customers. This finance journalist is aware there’s also a desire for similar products in aged care and live-in-care contexts, but you don’t see that as often.
Qoria as an umbrella brand ultimately provides software that allows remote configuration of settings, letting parents in particular introduce guardrails for children in an environment where Australia is trying to introduce a social media ban.
You generally don’t need to think hard about things online children shouldn’t be looking at to get an idea of the value proposition behind Qoria, here – which has been having a pretty good 2024 in terms of 1Y returns. (Consider also the cynical rise of Life360.)
This news relates to Japan, and not Australia, but it’s an interesting enough place for the stock to be based. (The company was formerly called Family Zone Cyber Safety Ltd.)
“Partnering with BBSS allows us to bring our cutting-edge digital wellbeing solutions to Japan, a market known for its high standards of technology and security,” Qoria CEO Viktorija Mliajeva said.
“Together, we’re committed to support and empower families with the tools they need to navigate the fast moving online world safely and responsibly.”
QOR last traded at 45cps.
Join the discussion: See what HotCopper users are saying about Qoria Ltd and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.